Physician profile
Asad Fraser
NPI 1497759286
$354,610.65
in general payments reported to CMS, 2019-2025
44 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $18K · 2021: $31K · 2022: $26K · 2023: $33K · 2024: $62K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Travel and Lodging: $15K · Food and Beverage: $15K · Consulting Fee: $12K · Education: $155 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,787.50 |
| Travel and Lodging | $14,803.03 |
| Food and Beverage | $14,524.07 |
| Consulting Fee | $11,910.00 |
| Education | $154.98 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $107,179.99 | 2019-2025 | Otezla, Tavneos, Otezla |
| Mallinckrodt Hospital Products INC. | $70,435.87 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $59,548.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $44,952.92 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $31,920.15 | 2019 | |
| Celgene Corporation | $14,222.33 | 2019-2021 | |
| Pfizer INC. | $8,239.17 | 2019-2025 | |
| Janssen Biotech, INC. | $6,308.41 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $2,858.54 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $2,277.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,247.96 | 2019-2025 | Benlysta, Nucala, Rotarix |
| Lilly USA, LLC | $692.58 | 2019-2024 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $592.90 | 2019-2025 | Orencia, Sotyktu |
| Radius Health, INC. | $536.38 | 2019-2025 | Tymlos |
| Janssen Scientific Affairs, LLC | $324.57 | 2021-2022 |
Show all 40 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.